InMed 8-K: Pre-clinical INM-901 Alzheimer’s results to be unveiled at AAIC

Rhea-AI Filing Summary

Form 8-K (Item 7.01 – Regulation FD): InMed Pharmaceuticals (Nasdaq: INM) announced it will present new pre-clinical data from its cannabinoid-based INM-901 program for Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC) 2025. The disclosure, dated 28 Jul 2025, is being furnished—not filed—so it carries no liability under Exchange Act §18 and will not be automatically incorporated into other SEC filings.

No financial results, guidance, or transactional details accompany the notice; the company simply alerts investors to an upcoming scientific presentation. Exhibit 99.1 (news release) and Exhibit 104 (XBRL cover data) are provided as furnished exhibits.

Because the information is limited to a pipeline update and occurs at the pre-clinical stage, any commercial or financial impact remains undetermined within the filing.

Positive

• Continued advancement of INM-901 Alzheimer’s program, demonstrating ongoing R&D commitment and conference-level recognition.

Negative

• No efficacy or safety data disclosed, leaving investors unable to gauge program viability or timeline.
• No financial metrics or guidance included; immediate valuation impact uncertain.

Insights

Healthcare Equity Analyst

TL;DR: Neutral 8-K; announces pre-clinical Alzheimer’s data presentation with no financials or guidance.

The filing signals continued R&D activity in INM-901 but offers no quantitative results, timelines, or regulatory milestones. As a Regulation FD item, it primarily ensures fair disclosure ahead of a conference. Absent efficacy data, market size commentary, or partnership news, the event is informational rather than value-changing. Investors may watch for data quality once publicly released, yet immediate valuation impact appears limited.

Biotech Industry Specialist

TL;DR: Pipeline progress acknowledged; materiality low until data are revealed.

AAIC is a reputable Alzheimer’s forum, so selection reinforces scientific credibility. Still, INM-901 remains pre-clinical; many such programs never reach IND. The lack of study parameters, endpoints, or comparative benchmarks prevents assessing differentiation or commercial potential. Therefore, the announcement is noteworthy for visibility but not impactful on financial outlook.

false 0001728328 A1 0001728328 2025-07-28 2025-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2025

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc.
Suite 1445 - 885 W. Georgia Street,
Vancouver, B.C.
Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 28, 2025, the Company announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer’s Association International Conference (AAIC) 2025, the world’s leading forum for Alzheimer’s disease(“AD”) and dementia research.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		News release, dated July 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.
Date: July 28, 2025	By:	/s/ Eric A Adams
		Eric A Adams
		President & CEO

2

FAQ

What did InMed Pharmaceuticals (INM) announce in its July 28 2025 8-K?

The company will present new pre-clinical data from its INM-901 Alzheimer’s program at AAIC 2025.

Does the filing include financial results or guidance for INM?

No. The 8-K is limited to a Regulation FD disclosure and furnishes no financial metrics or outlook.

What exhibits accompany this Form 8-K?

Exhibit 99.1 is the related news release; Exhibit 104 is the Cover Page Interactive Data File (Inline XBRL).

Is the information in Item 7.01 considered "filed" with the SEC?

It is furnished, not filed, and therefore not subject to Exchange Act §18 liability.

Why is AAIC 2025 significant for InMed’s INM-901 program?

AAIC is the leading global Alzheimer’s conference, providing visibility and peer review for early-stage research.